PEEP Vs. ZEEP in Out-of-Hospital-Cardiac-Arrest
Launched by MUEHLENKREISKLINIKEN, MKK · Feb 15, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways of providing breathing support to adult patients who have experienced an out-of-hospital cardiac arrest (OHCA), which is when the heart suddenly stops beating outside of a hospital. The study compares a technique called positive-end-expiratory-pressure (PEEP) to zero-end-expiratory-pressure (ZEEP) during resuscitation efforts. PEEP helps keep the airways open, while ZEEP allows them to close completely. The goal is to see which method helps more patients regain their heartbeat and improve their chances of survival.
To participate in this trial, individuals must be at least 18 years old and have had a non-traumatic cardiac arrest, meaning their heart stopped for reasons other than an injury. They should also require mechanical breathing support. Unfortunately, those under 18 years old, those with injuries causing their cardiac arrest, or anyone who has decided against resuscitation will not be eligible. The trial is not yet recruiting participants, but if eligible, participants can expect to contribute to important research that may help improve care for future patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults \>= 18 years
- • non-traumatic OHCA
- • mechanical ventilation via airway device
- Exclusion Criteria:
- • Patients \< 18 years,
- • traumatic cause of OHCA,
- • no cardiac arrest, withholding of resuscitation (e.g. Do-Not-Resuscitate orders)
About Muehlenkreiskliniken, Mkk
Mühlenkreis Kliniken (MKK) is a leading healthcare provider in Germany, renowned for its commitment to delivering high-quality medical services and innovative patient care. With a focus on advancing medical research and improving health outcomes, MKK actively engages in clinical trials across various therapeutic areas. The organization collaborates with multidisciplinary teams of healthcare professionals and researchers to ensure the highest standards of safety and efficacy in clinical studies. By fostering a culture of excellence and continuous improvement, MKK aims to contribute significantly to the advancement of medical science and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported